Associated Papers
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
40830613 (PubMed )
Supplement: 41598_2025_13667_MOESM2_ESM.xlsx › Supplementary_Table_3
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B et al.
Cancers, 2021
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
Zeng B et al.
Frontiers in Oncology, 2021
33889545 (PubMed )
Supplement: Table_6.xlsx › Sheet1
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2017
Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing.
Hiemenz MC et al.
Plos One, 2016
27043212 (PubMed )
Supplement: pone.0152851.s001.xlsx › EGFR
Select a paper to view details